You are viewing: US Human Organoids Market analysis
Part of: Human Organoids Market (Global)

The US Human Organoids Market was valued at $197.6 Million in 2024 and projected to reach to $398.1 Million by 2029, representing a compound annual growth rate of 15.0%. The US human organoids market is positioned for sustained expansion through 2029, driven by increasing adoption in pharmaceutical R&D, regenerative medicine, and precision medicine initiatives.

US Human Organoids Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Human Organoids Market Trends and Insights

  • This expansion reflects the US healthcare sector's increasing investment in regenerative medicine, personalized drug testing, and disease modeling technologies.
  • The US leads in research funding and biotech innovation, positioning the country as a critical hub for organoid development and commercialization. Driving the US market are advances in stem cell technology, rising pharmaceutical R&D spending, and growing adoption of organoids as alternatives to animal testing.
  • The US regulatory environment, supported by FDA guidance on organoid-based therapeutics, accelerates market penetration.
  • Additionally, US academic institutions and private biotech firms are pioneering organoid applications in oncology, neurology, and organ transplantation, further strengthening market momentum through 2029..

Key Market Statistics

  • CAGR (2024-2029) 15.0% CAGR
  • Market Size, 2024 ~USD 197.6 Million
  • Forecast, 2029 ~USD 398.1 Million
  • Country US

US Human Organoids Market Overview

Market Valuation :

The US human organoids market is valued at $197.6 million in 2024, with strong momentum driven by federal research funding and private biotech investment in regenerative medicine applications.

Rapid Growth Trajectory :

With a 15% CAGR through 2029, the US market is expanding faster than the global average of 14.4%, reflecting the country's leadership in organoid research and commercialization.

Research & Development Hub :

The US hosts world-leading academic institutions and biotech companies advancing organoid technology for drug discovery, toxicology testing, and personalized medicine applications.

Regulatory Support :

FDA initiatives and NIH funding programs are accelerating organoid adoption in pharmaceutical development, reducing reliance on animal testing and enabling faster clinical pathways.

US Human Organoids Market Dynamics

  • Major biotech firms and academic medical centers are investing heavily in organoid platforms for drug efficacy and safety testing, supported by favorable regulatory frameworks and substantial government funding.
  • The market's 15% CAGR reflects growing recognition of organoids as superior alternatives to traditional cell cultures and animal models.
  • Emerging applications in personalized cancer treatment and organ transplantation are expected to unlock new revenue streams.
  • However, standardization challenges and manufacturing scalability remain key considerations for market participants..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The US human organoids market is valued at $197.6 million in 2024 and is expected to double to $398.1 million by 2029, driven by a 15.0% CAGR.
    • The US pharmaceutical and biotech sectors are increasingly adopting organoids for drug discovery and personalized medicine, reducing reliance on animal models.
    • Strong US regulatory support and FDA guidance on organoid therapeutics create a favorable environment for market expansion and commercialization.
    • US research institutions and private biotech companies are leading innovation in organoid applications across oncology, neurology, and regenerative medicine.

    Human Organoids Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment DEVELOPMENTAL BIOLOGY (Application)
    Forecast Period 2024-2029
    Growth Rate CAGR of 14.4% from 2024 to 2029
    Largest Segment READY-TO-USE PRODUCTS (Type)
    Market Size Base Year (Billions) ~USD 1.19 (2024)
    Revenue Forecast (Billions) ~USD 2.33 (2029)
    Segments Covered Product, Type, Source, Culture Method, Disease Area, Application, End User

    US Human Organoids Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Product

    • Colorectal Models
    • Heart Models
    • Kidney Models
    • Liver Models
    • Lung Models
    • Other Products
    • Pancreatic Models

    By Type

    • 2D Colorectal Models
    • 2D Heart Models
    • 2D Kidney Models
    • 2D Liver Models
    • 2D Lung Models
    • 2D Models (Other Products)
    • 2D Pancreatic Models
    • 3D Bioprinted Colorectal Models
    • 3D Bioprinted Heart Models
    • 3D Bioprinted Kidney Models
    • 3D Bioprinted Liver Models
    • 3D Bioprinted Lung Models
    • 3D Bioprinted Models (Other Products)
    • 3D Bioprinted Pancreatic Models
    • 3D Colorectal Models
    • 3D Heart Models
    • 3D Kidney Models
    • 3D Liver Models
    • 3D Lung Models
    • 3D Models (Other Products)
    • 3D Pancreatic Models
    • Colorectal Organoids
    • Colorectal Spheroids
    • Cryopreserved Cells (Other Products)
    • Cryopreserved Colorectal Cells
    • Cryopreserved Heart Cells
    • Cryopreserved Hepatocytes
    • Cryopreserved Kidney Cells
    • Cryopreserved Lung Cells
    • Cryopreserved Pancreatic Cells
    • Customizable Products
    • Fresh Cells (Other Products)
    • Fresh Colorectal Cells
    • Fresh Heart Cells
    • Fresh Hepatocytes
    • Fresh Kidney Cells
    • Fresh Lung Cells
    • Fresh Pancreatic Cells
    • Heart Organoids
    • Heart Spheroids
    • Kidney Organoids
    • Kidney Spheroids
    • Liver Organoids
    • Liver Spheroids
    • Liver-On-A-Chip
    • Lung Organoids
    • Lung Spheroids
    • Organoids (Other Products)
    • Other 2D Colorectal Models
    • Other 2D Heart Models
    • Other 2D Kidney Models
    • Other 2D Liver Models
    • Other 2D Lung Models
    • Other 2D Models (Other Products)
    • Other 2D Pancreas Models
    • Other 3D Colorectal Models
    • Other 3D Heart Models
    • Other 3D Kidney Models
    • Other 3D Liver Models
    • Other 3D Lung Models
    • Other 3D Models (Other Products)
    • Other 3D Pancreatic Models
    • Pancreatic Organoids
    • Pancreatic Spheroids
    • Ready-To-Use Products
    • Spheroids (Other Products)

    By Source

    • Adult Stem Cells
    • Escs
    • Ipscs
    • Other Sources

    By Culture Method

    • 3D Bioprinting Culture
    • Air-Liquid Interface Culture
    • Matrigel Matrix Culture
    • Other Culture Methods
    • Suspension Culture

    By Disease Area

    • Cardiovascular Diseases
    • Gastrointestinal Diseases
    • Infectious Diseases
    • Liver Diseases
    • Neurological Disorders
    • Oncology
    • Other Disease Areas

    By Application

    • Developmental Biology
    • Disease Pathology
    • Drug Toxicity & Efficacy Testing
    • Other Applications
    • Personalized Medicine
    • Regenerative Medicine

    By End User

    • Academic & Research Institutes
    • Cros
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    US: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029

    Segment20222023202420252026202720282029CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES46.751.356.963.771.781.793.7108.213.7
    CROS128.4141.6157.9177.8201.2230.2265.4308.114.3
    OTHER END USERS14.615.817.419.321.524.227.531.412.6
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES196.2219.1247.3281.7322.7373.5435.5511.515.6
    TOTAL385.9427.8479.5542.4617.1709.6822.1959.214.9

    Target Audience

    • Pharmaceutical Companies : US pharma firms need market intelligence on organoid adoption rates, competitive offerings, and ROI metrics to optimize drug development pipelines and reduce time-to-market.
    • Biotech Startups & Scale-ups : Emerging organoid technology companies require detailed US market sizing, funding landscape analysis, and customer segmentation to refine go-to-market strategies and secure investor confidence.
    • Academic & Research Institutions : US universities and research centers need market data on commercialization opportunities, licensing potential, and industry partnerships to translate organoid research into revenue-generating ventures.
    • Medical Device & Diagnostics Firms : Companies developing complementary technologies require insights into organoid market dynamics, integration opportunities, and customer needs to position adjacent products effectively.
    • Healthcare Investors & Venture Capitalists : US-focused investors need comprehensive market forecasts, competitive analysis, and growth drivers to identify high-potential organoid companies and optimize portfolio allocation decisions.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise US market valuations ($197.6M in 2024, $398.1M by 2029) and segment-specific growth rates to benchmark competitive positioning and identify expansion opportunities.
    • Regional Investment Insights : Understand US-specific funding trends, venture capital flows, and government R&D spending driving organoid adoption across pharmaceutical, biotech, and academic sectors.
    • Competitive Landscape Analysis : Identify leading US organoid developers, research institutions, and commercial players to inform partnership strategies, M&A decisions, and market entry planning.
    • Application & End-User Segmentation : Gain detailed insights into US demand drivers across drug discovery, disease modeling, toxicology testing, and regenerative medicine to tailor product development and marketing strategies.
    • Regulatory & Reimbursement Framework : Navigate FDA approval pathways, insurance coverage trends, and healthcare policy developments specific to the US market to accelerate commercialization timelines.

    Frequently asked questions

    What is the current size of the US human organoids market?

    The US human organoids market was valued at $197.6 million in 2024 and is projected to reach $398.1 million by 2029.

    What is the expected growth rate for the US human organoids market?

    The US human organoids market is expected to grow at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2029.

    What are the primary drivers of growth in the US human organoids market?

    Key drivers include advances in stem cell technology, increased pharmaceutical R&D spending, adoption of organoids as alternatives to animal testing, and strong US regulatory support for organoid-based therapeutics.

    Which therapeutic areas are driving US organoid market adoption?

    The US market is being driven by applications in oncology, neurology, organ transplantation, and personalized drug testing, with significant investment from both academic and private biotech sectors.

    How does the US regulatory environment support the organoids market?

    The US FDA has provided guidance on organoid-based therapeutics and supports their use in drug discovery and disease modeling, creating a favorable regulatory pathway for commercialization and market growth.

    RESEARCH METHODOLOGY

    The study involved major activities in estimating the current market size for the human organoids market. Exhaustive secondary research was done to collect information on the human organoids industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the human organoids market.

    The four steps involved in estimating the market size are

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

    The following is a breakdown of the primary respondents:

    Human Organoids Market

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    COMPANY NAME DESIGNATION
    Thermo Fisher Scientific Inc. Director of sales
    Merck KGaA Sales Executive

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the human organoids market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • The revenues generated by leading players operating in the human organoids market have been determined through primary and secondary research.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    The research methodology used to estimate the market size includes the following:

    Human Organoids Market

    Data Triangulation

    After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic microanatomy. Organoids are derived from one or a few cells from tissue, embryonic stem cells, or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities.

    Stakeholders

    • Senior Management
    • End User
    • Finance/Procurement Department  
    • R&D Department

    Report Objectives

    • To define, describe, segment, and forecast the global human organoids market, by product, source, type, culture method, disease area, application, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall human organoids market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, Latin America, and GCC Countries
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
    • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

     

    Get the Full Human Organoids Market Report

    Full forecast, segment splits, and company analysis for all Human Organoids Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status